Eterna focuses on developing innovative off-the-shelf cellular therapies using iPSC-derived mesenchymal stem cells to target solid tumors. The company claims to enhance T-cell anti-tumor activity while limiting systemic exposure.

Eterna

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

COM:ETERNATX

Eterna

Last Close

0.53

22/11 21:00

Market Cap

9.90M

Beta: -

Volume Today

113.60K

Avg: -

Filings Not Available